Evidence map›Paper›PMID 36439552›Full record

ArticleFrontiers in urology2022

Targeting Bladder Urothelial Carcinoma with pHLIP-ICG and Inhibition of Urothelial Cancer Cell Proliferation by pHLIP-amanitin.

Anna Moshnikova, Borivoj Golijanin, Ali Amin, Joshua Doyle, Ohad Kott, Boris Gershman, Michael DuPont, Yujing Li, Xiongbin Lu, Donald M Engelman and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Nucleic acid drugs: recent progress and future perspectives.Signal transduction and targeted therapy · 2024
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anna MoshnikovaPhysics Department, University of Rhode Island, Kingston, RI, USA.
Borivoj GolijaninDepartment of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI, USA.
Ali AminDepartment of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI, USA.
Joshua DoylePhysics Department, University of Rhode Island, Kingston, RI, USA.
Ohad KottDivision of Urology, Department of Surgery, Brown University, The Miriam Hospital, Providence, RI, USA.
Boris GershmanDivision of Urology, Department of Surgery, Brown University, The Miriam Hospital, Providence, RI, USA.
Michael DuPontPhysics Department, University of Rhode Island, Kingston, RI, USA.
Yujing LiDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Xiongbin LuDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Donald M EngelmanDepartment of Molecular Biophysics and Biochemistry, Yale, New Haven, CT, USA.
Oleg A AndreevPhysics Department, University of Rhode Island, Kingston, RI, USA.
Yana K ReshetnyakPhysics Department, University of Rhode Island, Kingston, RI, USA.
Dragan GolijaninDivision of Urology, Department of Surgery, Brown University, The Miriam Hospital, Providence, RI, USA.

Funding

Training CoreP20GM103430 · NIGMS · UNIVERSITY OF RHODE ISLAND · PI Christopher Lee Hemme · 2012 to 2026
$63.6M
TM INTERACTIONS IN MEMBRANE PROTEIN FOLDING AND FUNCTIONR01GM073857 · NIGMS · YALE UNIVERSITY · PI ANDREEV, OLEG A, ENGELMAN, DONALD M. · 2006 to 2023
$8.4M
Targeting Human Cancers with Hemizygous Deletion of TP53R01CA203737 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, XIONGBIN, SCHNEIDER, BRYAN PAUL · 2016 to 2023
$3.4M
NCI NIH HHS R01 CA203737NIGMS NIH HHS P20 GM103430NIGMS NIH HHS R01 GM073857
6 · The paper itself

Abstract

Acidity is a useful biomarker for the targeting of metabolically active-cells in tumors. pH Low Insertion Peptides (pHLIPs) sense the pH at the surfaces of tumor cells and can facilitate intracellular delivery of cell-permeable and cell-impermeable cargo molecules. In this study we have shown the targeting of malignant lesions in human bladders by fluorescent pHLIP agents, intracellular delivery of amanitin toxin by pHLIP for the inhibition of urothelial cancer cell proliferation, and enhanced potency of pHLIP-amanitin for cancer cells with 17p loss, a mutation frequently present in urothelial cancers. Twenty-eight

Indexed as

imagingintravesical instillationpH-dependent deliverysuperficial bladder cancersurgerytreatmenttumor acidity

Identifiers

PMID36439552
PMCPMC9691284

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.